Navigation Links
New Data Published in The Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Date:11/23/2007

n rotavirus derived from the most common human rotavirus strain with the goal of offering protection against the most commonly circulating and emerging rotavirus serotypes by mimicking the protective effects of natural human rotavirus infection," said David I. Bernstein, MD, MA, Director, Infectious Diseases; Gamble Program at Cincinnati Children's Hospital Medical Center. "These data are important because they confirm that immunization with two doses of the rotavirus candidate vaccine could provide broad protection against rotavirus gastroenteritis caused by emerging types in addition to those that are already commonly circulating."

In an additional analysis, protection against severe rotavirus gastroenteritis in the period between dose one and dose two was observed to be 90%. The protection offered by the two-dose schedule of this rotavirus vaccine observed as early as after dose one is particularly relevant as severe dehydrating rotavirus gastroenteritis can occur in infants as young as three months of age.

Since rotavirus is highly infectious, the spread of the disease may be difficult to control. Vaccination against rotavirus is recognized as the best measure to protect children against rotavirus disease and has been shown to be highly effective in preventing the disease.

The CDC Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) recommend that infants receive routine vaccination with the rotavirus vaccine currently licensed by the FDA at two, four, and six months of age in order to prevent rotavirus gastroenteritis.

GSK's Biologics License Application (BLA) for the candidate rotavirus vaccine is currently under review by the U.S. Food and Drug Administration (FDA). It is proposed that the vaccine would be given in two oral doses beginning at six weeks of age and completed by 24 weeks of age, with a minimum four-week interval between the
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Una presentazione speciale durante la settimana della prevenzione ... di MERG valutare i successi ottenuti grazie all,adozione ... popolazioni di pazienti affetti dalla patologia. ... Fass , MD della Case Western Reserve University, ha ... alla terapia Stretta. Un panel di esperti ha quindi ...
(Date:5/27/2015)... -- Biosensors International Group, Ltd. ("Biosensors " or the ... developer, manufacturer and marketer of innovative medical devices, today ... FY15") and fiscal full year ended 31 March 2015 ... , Q4 FY15: , Total revenue of ... Fiscal Year 2014 ("Q4 FY14") due to licensing revenue ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. ... John P. McLaughlin , the company,s president and chief ... Healthcare Conference next week in New York City.  The ... June 3, 2015 at 11:30 a.m. EDT. ... the presentation, go to the Company,s website at ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... TRIANGLE PARK, N.C., Jan. 6, 2011 CeNeRx BioPharma, Inc., today ... new formulation of TriRima ™, the company,s novel antidepressant in ... it will be presenting at Biotech Showcase™ ... 11:00 AM PST. TriRima is a member ...
... Pharmasset, Inc. (Nasdaq: VRUS ), announced today positive ... HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase ... dual nucleotide study.   Pipeline Update and ... PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a ...
Cached Medicine Technology:CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 2CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 3Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 ... the first healthcare provider along the Gulf Coast ... management (CCM). In partnership with MD Revolution, a ... a new program that enables healthcare providers to ... reimbursements. This new, user-friendly program is designed to ...
(Date:5/27/2015)... May 27, 2015 CompanionDx ... and somatic genomic analysis in personalized cancer therapy: Non-small ... the American Society of Clinical Oncology (ASCO) as part ... in Chicago. , The molecular and clinical data used ... Atlas (TCGA) database. The study reports improved patient outcomes ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
(Date:5/27/2015)... Dallas, Texas (PRWEB) May 27, 2015 ... on the current state of the Omega-3 industry. ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ... Products, Gc Rieber Oils, Camanchaca Fishing Company, Seadragon ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... West Indies cricket captain Brian Lara has thrown a punch ... opening of a cancer center named after him. ... and management of the Brian Lara Cancer Center for their ... "missed" the (West Indies) the Cricket Board. ,His ...
... people with celiac disease are waiting an average of 13 ... gut disorder caused by gluten intolerance, and can lead to ... is a protein group found in wheat and other flours ... the carbon dioxide (CO2) produced by the yeast and expands ...
... all the wrong reasons. ,Civic authorities ... who use the Hudson River of the potential health problems ... the river after a main broke Friday afternoon. ... in contact with the sewage and ingesting bacteria that could ...
... the seizure drug valporate, which is marketed by Abbott ... their risk of having an infant with mental ... annual meeting of the American Academy of Neurology in ... Meador, professor of neurology at the University of Florida, ...
... underwent a simultaneous liver and kidney transplant at a ... claimed as the first such in the world. ... as primary Hyperoxaluria, in which the liver lacks an ... bones, heart and pancreas. Patients suffering from the disease ...
... who are on estrogen therapy before the age of 65. ... risk of Alzheimers disease or dementia. ,The study showed ... the age of 65 cut their risk of dementia by 50%, ... the age of 65. ,This study was part ...
Cached Medicine News:Health News:Gluten Intolerance Cases Diagnosed Late in UK 2Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:NRI Boy Underwent a Rare Dual Transplant Surgery 2
Inquire...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
500L...
Medicine Products: